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Abstract
Background: Bladder cancer is a significant healthcare problem in the United States of America with a high
recurrence rate. Early detection of bladder cancer is essential for removing the tumor with preservation of the
bladder, avoiding metastasis and hence improving prognosis and long-term survival. The objective of this study
was to analyze the presence of DEK protein in voided urine of bladder cancer patients as a urine-based bladder
cancer diagnostic test.
Methods: We examined the expression of DEK protein by western blot in 38 paired transitional cell carcinoma
(TCC) bladder tumor tissues and adjacent normal tissue. The presence of DEK protein in voided urine was analyzed
by western blot in 42 urine samples collected from patients with active TCC, other malignant urogenital disease
and healthy individuals.
Results: The DEK protein is expressed in 33 of 38 bladder tumor tissues with no expression in adjacent normal
tissue. Based on our sample size, DEK protein is expressed in 100% of tumors of low malignant potential, 92% of
tumors of low grade and in 71% of tumors of high grade. Next, we analyzed 42 urine samples from patients with
active TCC, other malignant urogenital disease, non-malignant urogenital disease and healthy individuals for DEK
protein expression by western blot analysis. We are the first to show that the DEK protein is present in the urine of
bladder cancer patients. Approximately 84% of TCC patient urine specimens were positive for urine DEK.
Conclusion: Based on our pilot study of 38 bladder tumor tissue and 42 urine samples from patients with active
TCC, other malignant urogenital disease, non-malignant urogenital disease and healthy individuals; DEK protein is
expressed in bladder tumor tissue and voided urine of bladder cancer patients. The presence of DEK protein in
voided urine is potentially a suitable biomarker for bladder cancer and that the screening for the presence of DEK
protein in urine can be explored as a noninvasive diagnostic test for bladder cancer.
Background
Bladder cancer is the sixth most prevalent malignancy in
the United States of America, with an expected 70,530
newly diagnosed cases in 2010, and 14,680 deaths [1].
More than 90% of bladder cancers are transitional cell
carcinomas (TCC), 5% are squamous cell carcinomas,
and less than 2% are adenocarcinomas. Urothelial
tumors are classified into four categories: papilloma,
papillary urothelial neoplasm of low malignant potential,
low grade carcinoma, and high grade carcinoma [2]. Of
all newly diagnosed cases of transitional cell carcinomas,
about 75% present as superficial tumors. Of those
superficial tumors, 50 to 70% will recur and roughly 10
to 20% will progress to aggressive invasive disease [3].
Patients are therefore kept under surveillance for early
detection of recurrences. Early and accurate detection of
bladder cancer will allow for effective treatment of blad-
der cancer patients, hence improving prognosis and
long-term survival.
Cystoscopy, the current “gold standard” clinical proce-
dure to detect bladder cancer is an invasive, unpleasant
and expensive method with poor patient compliance.
Urine-based detection of bladder cancer biomarkers
aims to replace or reduce the use of cystoscopy for diag-
nosis and surveillance of bladder cancer. However, urine
cytology, and many of the currently developed FDA
approved urine biomarkers including detection of chro-
mosomal aneuploidy and deletion using fluorescence
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®) have limited sensitiv-
ity for detection of low stage and grade tumors that
form the main group that recur [4,5]. Therefore, there is
a need for more sensitive urinary biomarkers, exempli-
fied by recent data regarding epigenetic [6] and protein
biomarkers[7], that can be implemented in molecular
diagnostic laboratories
The DEK protein was initially identified as a fusion
protein with CAN nucleoporin in a subtype of acute
myeloid leukemia involving the t(6;9) chromosomal
translocation[8]. The oncogene DEK is overexpressed in
several malignancies including melanoma, hepatocellular
carcinoma, glioblastoma, retinoblastoma, and bladder
cancer [9-11]. Furthermore, autoantibodies to DEK have
been detected in juvenile rheumatoid arthritis [12],
systemic lupus erythematosus and sarcoidosis [13].
Proto-oncogenic roles of DEK includes the ability to
inhibit p53 mediated apoptosis [14], cooperate with the
viral oncogene E6 and E7 to overcome senescence [15]
and promote epithelial transformation in vitro and
in vivo when overexpressed [16].
A region of genomic gain on chromosome 6p22 that
has been detected in high grade bladder cancer tumors
contains the DEK gene [9]. cDNA microarray analysis of
bladder tumor tissues found DEK as one of the genes
significantly overexpressed in early stage bladder tumors
[ 1 7 ] .H o w e v e r ,t h e r ei sn op u b l i s h e dl i t e r a t u r et os u p -
port increased DEK protein levels in bladder tumors
and in the urine of bladder cancer patients.
Here we show that oncoprotein DEK can be used as a
biomarker for detection of bladder cancer using patient
urine samples. We evaluated DEK protein levels in blad-
der tumor tissues and found high levels of DEK protein
in tumor tissue with no expression in adjacent normal
bladder tissue. Next, we determined if the DEK protein
is present in urine of bladder cancer patients. We are
the first to show that DEK protein can be detected in
the urine of bladder cancer patients by western blot ana-
lysis using a commercially available polyclonal DEK
antibody.
Methods
Tissue specimen collection and protein isolation
Bladder tumor tissue and corresponding noncancerous
bladder tissues were obtained from consented patients
under Israeli Ministry of Health (Protocol no. 902008-
0588) and Institutional Review Board (Protocol no.1091)
approved protocols from Wolfson Medical Center,
Holon, Israel.
All patients had positive findings on initial diagnosis
by cystoscopy. Tissue samples were immediately frozen
after removal and stored at - 80°C. A section of the
tumor tissue was sent for histologic diagnosis to deter-
mine tumor grade and stage and results were sent along
with the samples. The patients’ background and clinical
data are summarized in Table 1.
Cold cut frozen tissue samples were homogenized in
RIPA buffer (150 mM NaCl, 0.01 M sodium pyropho-
sphate, 10 mM EDTA, 10 mM sodium fluoride, 50 mM
Tris pH 8.8, 0.1% SDS, 12.8 mM deoxycholic acid, 10%
glycerol, 1% NP-40) using a mortar and pestle. Sixty
(60) ug of tissue extracts were resolved on a 10% SDS-
PAGE gel and analyzed for DEK expression by western
blot using a monoclonal antibody (BD Bioscience, San
Diego, CA).
Urine specimen collection and protein isolation
Under Israeli Ministry of Health (Protocol no. 902008-
0588) and Institutional Review Board (Protocol no.1091)
approved protocols from Wolfson Medical Center,
Holon, Israel, voided urine from patients with bladder
cancer (i.e., TCC), prostate cancer (i.e., CAP) and renal
cancer (i.e., RCC) were collected on the day of surgery
Table 1 Patient population and characteristics
Bladder Cancer (TCC) Tissue Urine
Total number 38 19
Mean age (range) 76 (53-87)
years
74 (53-85)
Gender
Male 32 17
Female 6 2
Grade
Low malignant potential 10 3
Low grade 14 8
High grade 14 8
Stage
Superficial (pTa) 18 10
Invasive (≥ pT1) 20 9
Prostate Cancer (CaP)
Total number - 7
Mean age (range) - 60 (55-71)
years
Renal Cell Carcinoma (RCC)
Total number - 4
Mean age (range) - 61(53-72)
years
Healthy
Total number - 6
Mean age (range) - 37(32-49)
years
Suspected TCC and pathological
diagnosis
Total number 6 6
Cystitis/ Chronic Inflammation 3 3
Squamous metaplasia and BPH 1 -
No tumor 2 1
Benign renal tumor - 2
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ground and clinical data are summarized in. Urine sam-
ples (~20-50 ml aliquots) were stored in the presence of
a protease inhibitor tablet (Roche, Indianapolis, IN) and
maintained at -80°C.
Proteins from 20 ml of urine were precipitated with
two volumes of ice-cold acetone and incubated at -20°C
for 1 hour. Post centrifugation, the acetone precipitated
protein pellet was suspended in 2 ml of sucrose buffer
(10 mM triethanolamine and 250 mM sucrose). Four
hundred (400) μl of the resuspended urine protein was
further concentrated using a 3K Microcon
® filter and
was subjected to western blot analysis using a polyclonal
DEK antibody (Bethyl laboratories, Montgomery, TX).
Cell Lines
Human bladder cancer cell lines T-24 and RT-4 were
maintained in McCoy’s 5A medium supplemented with
10% fetal bovine serum (FBS) and human bladder cancer
cell lines 5637 and TCCSUP were maintained in RPMI
supplemented with 10% FBS. SV-40 transformed human
bladder urothelial cell line (i.e., UroTSA cell line) was
maintained in DMEM medium supplemented with 10%
FBS. Human bladder epithelium progenitor cell line (i.e.,
HBEP) (CELL N TEC
®, Stauffacherstrasse, Bern, Swit-
zerland) was maintained in CnT-58 medium. Differen-
tiated epithelial cells were maintained in accordance
with the manufacturer’s protocol (CELL N TEC
®, Stauf-
facherstrasse, Bern, Switzerland). All cell lines were
maintained at 37°C in 5% CO2.
Whole Cell Lysates from Cell Lines
Prior to cell lysis, cultured cells were washed with 10 ml
of cold PBS. Cells were lysed using 1 ml of RIPA buffer
supplemented with protease inhibitors (Roche, Indiana-
polis, IN) at a concentration of 1 μg/μl. Lysed cells were
scraped and transferred to a 1.5 ml centrifuge tube and
centrifuged at 14,000 rpm for 10 minutes to collect
supernatant (i.e., whole cell lysates).
DEK Knockdown and DEK Overexpressing Cell Line
A lentiviral vector containing the DEK shRNA (pGIPZ-
DEK shRNA) (cat. no. RHS4430-99137795) was pur-
chased from Open Biosystems (ThermoScientific,
Huntsville, AL). To prepare DEK-shRNA lentivirus, 5 ×
10
5 293FT cells were first transfected with 10 μgo f
pGIPZ-DEK shRNA and 5 μg of the packaging vectors
(i.e., pCMVΔR8.2 and pHCMV-G) and grown at 37°C in
5% CO2. Supernatants of the transfected cells (contain-
ing lentivirus particles) were collected at 24 and 48
hours post-transfection. To obtain the DEK knockdown
5637 cell line, 5637 cells were transduced with DEK
shRNA lentiviral particles and selected using 2.5 μg/μl
puromycin (Sigma-Aldrich, St. Louis, MO).
DEK cDNA (NCBI Accession No. NM_003472.3) was
cloned into a pLenti GATEWAY
® lentiviral vector and
packaged as virus using ViraPower™ BSD Packaging
Mix (Invitrogen, Carlsbad, CA). Five (5) ml of the virus-
containing filtrate was spread onto a 10 mm tissue cul-
ture dish containing confluent 5637 cells. Cells were
selected for DEK-V5 expression at 48 hours using 10
μg/μl blasticidin (Invitrogen, Carlsbad, CA).
Results
DEK expression in bladder cancer cell lines
Previous studies based on tissue microarray data indi-
cated that DEK mRNA is overexpressed in bladder
tumors [17]. To test if high levels of DEK protein are
present in bladder cancer cell lines, we prepared whole
cell lysates using RIPA buffer from bladder cancer cell
lines RT-4, 5637, T-24 and TCCPSUP derived from
increasing grades of bladder cancer. We also prepared
lysates from UroTSA cells which are normal bladder
epithelial cells transformed with SV-40 T-antigen.
Western blot analysis was performed using a DEK
monoclonal antibody (BD Biosciences). Results from
western blot analysis indicate that DEK is expressed in
all bladder cancer cell lines as well as in normal blad-
der epithelial cell line UroTSA. (Figure 1A). To test if
DEK is present in only proliferating cells, we used
human bladder epithelial progenitor cell line (HBEP)
that proliferate in growth media and induced them to
a non-cycling differentiated state with 1 mM calcium
chloride. Lysates were prepared from HBEP and differ-
entiated HBEP and analyzed by western blot using the
DEK monoclonal antibody. Results indicate that DEK
protein is lost upon differentiation of primary cells
(Figure 1A).
Previous studies have demonstrated that patients with
Juvenile Rheumatoid Arthritis (JRA), have auto-antibo-
dies against DEK protein [12] and DEK protein is found
to be secreted in the synovial fluid of JRA patients [18].
To test if bladder cancer cells also secrete DEK protein,
we analyzed conditioned media obtained from bladder
cancer cell line 5637. Furthermore, we established two
stable cell lines: one that overexpressed DEK protein
with a V5 tag in the 5637 cell line (5637DEK-V5) and
the other expressing DEK shRNA to knockdown DEK
expression (5637 DEK shRNA). Conditioned media from
these two cell lines were also analyzed for DEK
expression.
Results show that DEK is absent in the conditioned
media of bladder cancer cell line 5637 indicating that
DEK may not be secreted by bladder cancer cells
(Figure 1B). Furthermore, even overexpression of DEK
protein in 5637 cell line (5637 DEK-V5) did not result
in secretion of DEK protein in the conditioned media
(Figure 1B).
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Several reports indicate that DEK is associated with blad-
der tumor tissue, which includes mRNA overexpression
studies by microarray [10,17] and amplification of 6p22.3
region of chromosome, wherein the DEK gene is located,
in 25% of advanced stage bladder cancer [9]. We wanted
to test if DEK protein is expressed in bladder tumor tis-
sue samples as compared to adjacent normal tissue. We
obtained 38 TCC tissue samples, confirmed by pathology
from Wolfson Medical Center, Holon, Israel.
Whole cell lysates were prepared from tumor tissue and
adjacent normal tissue samples and analyzed by western
blot using a DEK monoclonal antibody (BD Biosciences).
Results show that 33 out of 38 (86%) TCC tumor tissues
of both low and high grade were positive for the presence
of DEK protein with no detectable levels of DEK protein
in the adjacent normal tissues (Figure 2). DEK protein is
present in 100% of low malignant potential (LMP) TCC
tissue and 93% in low grade TCC whereas only 71% of
high grade tumor tissues were positive for DEK expression
(Table 2). We were unable to detect DEK in four high
grade TCC and one low grade TCC.
In our study we had five (5) samples from patients
who were suspected of bladder tumor by cystoscopy or
by the presence of gross hematuria but upon pathologi-
cal analysis of surgically removed suspected areas, the
tissues were found negative for tumor. However, by
western blot analysis of another segment of the tissue
we found DEK protein to be present in 2 out of the 5
samples. We cannot rule out the possibility that DEK
protein may be present in the bladder tissue of patients
with cystitis. Overall, our data further strengthens the
association of DEK with bladder cancer and as a poten-
tial marker of bladder cancer.
DEK expression in urine
Our data indicates that DEK protein is present only in
bladder tumor tissue. As urine contains both cells
Figure 1 DEK expression in cell lines. A. Whole cell lysates were
prepared from bladder cancer cell lines (RT-4, 5637, T-24 and
TCCSUP), Urothelial cell line (UroTSA) and undifferentiated and
differentiated progenitor bladder epithelial cell lines. DEK protein
was evaluated by western blot analysis using a DEK monoclonal
antibody (BD Bioscience). b-actin was used as a loading control. B.
Expression of DEK protein in whole cell (WC) lysate and respective
conditioned media from 5637, 5637 expressing nonspecific shRNA
(Ns shRNA), DEK shRNA or overexpressing DEK with a V5 tag (DEK-
V5) by western blot assay using a monoclonal DEK antibody.
Bottom panel represents a Coomassie stained gel to show that
equal amounts of proteins were loaded on the gel.
Figure 2 DEK expression in bladder tumor tissue. Tissue lysates
from bladder tumor tissue (T) or paired adjacent normal tissue (N)
were analyzed by western blot using DEK monoclonal antibody (BD
Biosciences). An established bladder SV-40 transformed urothelial
cell line (UroTSA) lysate was used as a positive control. b-actin was
used as a loading control. Sample MDL815 represents a biopsy
confirmed inflamed tissue from bladder (no tumor present). Three
representative western blots are shown.
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well as proteins from either secretion or cell lysis, we
wanted to test if DEK protein can be detected in the
urine of patients with TCC. Forty-two (42) voided urine
samples from patients with active bladder cancer (TCC),
prostate cancer (CAP), renal cancer (RCC), healthy sub-
jects and urine from patients with suspected TCC which
were found positive for nonmalignant conditions (NMC)
by pathology, were analyzed for the presence of DEK
protein. Results show that DEK protein is detected in
16 out of 19 urine samples of bladder cancer patients
(Figure 3). The DEK protein is detected in the urine of
patients with both low and high grade TCC. Based on
the indicated sample size, the sensitivity and specificity
of detecting DEK in the urine of bladder cancer patients
were 84% and 83% respectively with a positive predictive
value of 80% and negative predictive value of 86%
(Table 3). However, we also detected DEK protein in
the urine of some prostate and renal cancer patients
indicating that DEK protein may be overexpressed in
some prostate and renal cancer tumors.
Upon comparison of DEK protein levels in tissue and
in the voided urine from TCC patients, we found 12 out
of 18 samples were consistent for DEK expression in
tumor tissue and voided urine. Six (6) samples had DEK
protein expression in either tissue or voided urine. How-
ever, the two inflammation samples that were positive
for DEK in tissue were found to be negative for the pre-
sence of DEK protein in voided urine. (Table 4)
Discussion
As bladder cancer has the highest recurrence rate as
compared to any other malignancies, diagnostic and dis-
ease monitoring tools that can provide high specificity
and sensitivity would be of great interest in urological
oncology providing enormous benefit to patients, parti-
cularly if the specimens could be obtained noninvasively.
The overall goal of this study was to determine if the
expression of the DEK oncoprotein might serve as a bio-
marker for the detection of bladder cancer. Several stu-
dies indicated that DEK is overexpressed in bladder
tumors. One of the most consistently amplified regions
in advanced bladder cancers is located at 6p22.3 [19].
Oncogene DEK is located within this region. Further-
more, using bladder tumor cDNA microarrays, DEK
mRNA was significantly up regulated in bladder cancer
[10,17]. Based on these studies, one would predict that
DEK protein might be associated with the development
of bladder cancer.
In this study, we have identified DEK as a potential
urinary and tissue biomarker for TCC of the bladder of
both low and high grade, stage and progression. Eighty-
six percent (86%) of bladder tumor tissues were found
to be positive for DEK protein expression. Based on our
data obtained from a relatively small sample size of 38
tumor samples, DEK protein is present in most low
grade tumor tissue as compared to high grade.
We are the first to show that DEK protein is present
in the voided urine of patients with TCC of both low
and high grade. Based on our study, the presence of
DEK protein is largely specific for bladder cancer with a
few cases wherein DEK protein is present in renal and
prostate cancer. This study is limited to detection of
DEK protein in the urine of diagnosed TCC patients
with first incidence or recurrence of bladder cancer and
not in high risk individuals. Furthermore, we have a lim-
ited number of healthy individuals that are not age
matched to the TCC and other malignant urogenital
disease group.
We acknowledge that the presented data is based on a
small sample size. However, based on our pilot study,
oncoprotein DEK is a promising biomarker of bladder
cancer. Furthermore, the presence of DEK protein in
Table 2 DEK tissue expression in different grades of TCC
TCC
Tumor Grade
DEK WB LMP Low High NAT NMC
Positive 10 13 10 0 2
Negative 0143 83
DEK protein expression by western Blot (WB) in transitional cell carcinoma
(TCC) tissue, Normal adjacent tissue (NAT) and tissue from nonmalignant
conditions (NMC). LMP represents low malignant potential grade.
Figure 3 D E Ke x p r e s s i o ni nu r i n e .T h i r t y( 3 0 )u lo fa c e t o n e
precipitated urine protein lysates were analyzed by western blot
using a polyclonal DEK antibody (Bethyl Laboratories). An
established bladder SV-40 transformed urothelial cell line (UroTSA)
lysate was used as a positive control. CAP indicates prostate cancer,
RCC indicates renal cell carcinoma, H.TCC indicates history of
transitional cell carcinoma and TCC indicates transitional cell
carcinoma of the bladder. Voided urine sample, MDL 494* was
collected from a suspected TCC patient but pathology report was
inconclusive. Two representative western blots are shown.
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tion of DEK protein in the urine of patients as an attrac-
tive diagnostic for bladder cancer. We are encouraged to
further analyze DEK as a biomarker of bladder cancer
using larger number of patient samples that will allow
us to further strengthen the presence of DEK protein in
the urine of bladder cancer patients as a biomarker for
bladder cancer. We analyzed a small number of prostate
and renal cancer sample and we detected DEK in 16%
and 50% of prostate and renal cancer respectively. We
cannot rule out the possibility that DEK may be present
in renal cancer. Therefore, we propose to analyze larger
number of urine samples obtained from prostate and
renal cancer patients to address this concern. We are in
the process of initiating a prospective study involving
three different centers, in which we will test the pre-
sence of urine DEK in suspected TCC patients, age
matched healthy individuals, other malignant and non-
malignant urogenital disease patients and confirmed
TCC cases.
As western blot analysis may not be the choice
method for diagnostics, we are currently in the process
of developing a DEK ELISA for sensitive and specific
detection of DEK protein in voided urine sample. For
DEK to be adopted into clinical use, DEK must signifi-
cantly improve the predictive ability of current biomar-
kers. We will be comparing our assay with the FISH
based test UroVysion
® and other urine based biomar-
k e r sl i k eN M P 2 2 .W ec a n n o tr u l eo u tt h ep o s s i b i l i t y
that DEK alone may not be as accurate as cystoscopy
Table 3 Detection of DEK protein in voided urine
TCC CAP RCC
Tumor grade Gleason’s Score Clear Cell Type:
Fuhrman’s Grade
Papillary Cell Type:
Fuhrman’s Grade
DEK WB LMP Low High 6
(3+3)
7
(3+4)
1 2 3 Unknown Healthy NMC
Positive 367 1 0 001 1 0 1
Negative 021 4 2 110 0 6 5
The presence of DEK protein in voided urine by western Blot (WB) in transitional cell carcinoma (TCC), Prostate cancer (CAP), renal cell carcinoma (RCC) and
nonmalignant conditions (NMC). LMP represents low malignant potential grade.
Table 4 Comparison of DEK protein expression in tissue sample and voided urine from patients with TCC
Sample ID Clinical Data Urine Tissue (T/N)
MDL196 TCC Ta low malignant potential positive +/-
MDL185 TCC Ta low malignant potential positive +/-
MDL492 TCC Ta low malignant potential (I) positive +/-
MDL616 TCC Ta low grade (I-II) positive +/-
MDL254 TCC Ta low grade (I) positive +/-
MDL503 TCC Ta low grade(II) positive +/-
MDL709 TCC Ta low grade (I) positive +/-
MDL812 TCC Ta low grade (I) with squamous differentiation positive -/-
MDL377 TCC Ta low grade (II) negative +/-
MDL239 TCC T1 low grade negative +/-
MDL387 TCC T1 high grade with pappilary+ solid pattern positive +/-
MDL946 TCC T1 high grade(III) + CIS with solid pattern positive +/-
MDL026 TCC T1 high grade positive +/-
MDL046 TCC T2 high grade + CIS positive +/-
MDL215 TCC T2 high grade positive -/-
MDL911 TCC T2 high grade (III) positive -/-
MDL773 TCC T2 high grade (III)& Papillary RCC type1 negative +/-
MDL717 TCC T2 high grade (III) positive +/-
MDL300 Cystitis negative +/-
MDL612 Chronic Inflammation negative +/-
T: tumor tissue.
N: normal adjacent tissue.
Grey indicates the discrepancy in results between urine DEK expression and tissue DEK.
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DEK with other urinary biomarker may be as predictive
as cystoscopy. Nonetheless, detection of DEK protein in
voided urine samples alone or in combination with
other biomarkers, if successfully validated, will provide a
sensitive and noninvasive method of testing for bladder
cancer and subsequent recurrences.
Conclusion
This pilot study demonstrated that DEK protein is over-
expressed in bladder tumor tissue but not in adjacent
normal tissue. Furthermore, the DEK protein is present
in the voided urine of patients with bladder cancer. The
DEK protein is present in the voided urine of patients
with low and high grade bladder cancer. These results
indicate that the detection of the DEK protein in the
voided urine may potentially be used as a diagnostic test
for detection and surveillance of bladder cancer.
Acknowledgements
We thank Pnina Nir (Dept. of Urology, The E. Wolfson Med. Ctr. Holon, Israel)
for coordinating the collection of clinical samples. We thank Dr. Jack Mydlo
(Dept. of Urology, Temple University, Philadelphia, PA) for his expert advice
and guidance.
Author details
1Oncoveda, Tumor Biology Center, Medical Diagnostic Laboratories, A
Division of Genesis Biotechnology Group, Hamilton, New Jersey, USA.
2Department of Urology, The E. Wolfson Medical Center, Holon, Israel and
the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Authors’ contributions
All authors read and approved the final manuscript. AD was responsible for
study design, experimental job, interpretation of the results and writing the
manuscript. JPT contributed towards the conception and design of the
study, interpretation of the results and critically reviewed and edited the
manuscript. YM was responsible for data collection. MEA, EM, and AAS were
responsible for data analysis and interpretation of the study.
Competing interests
Financial competing interests: The authors AD, JPT, MEA and EM are
employees of Medical Diagnostic Laboratories, a division of Genesis
Biotechnology Group, Hamilton, New Jersey, United States of America.
The research presented in this manuscript and article-processing charge for
this manuscript is funded by Medical Diagnostic Laboratories.
The authors AD and JPT are named inventors on a patent application which
includes data presented in this manuscript.
Received: 8 January 2011 Accepted: 10 June 2011
Published: 10 June 2011
References
1. Society AC: Cancer Facts and Figures 2010. American Cancer Society
Altanta; 2010.
2. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet 2009,
374:239-249.
3. Hurst RE: Does the biomarker search paradigm need re-booting? BMC
Urol 2009, 9:1.
4. Van Tilborg AA, Bangma CH, Zwarthoff EC: Bladder cancer biomarkers and
their role in surveillance and screening. Int J Urol 2009, 16:23-30.
5. Budman LI, Kassouf W, Steinberg JR: Biomarkers for detection and
surveillance of bladder cancer. Can Urol Assoc J 2008, 2:212-221.
6. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M,
Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, et al: Three
epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict
bladder cancer from DNA-based analyses of urine samples. Clin Cancer
Res 16:5842-5851.
7. Jamshidian H, Kor K, Djalali M: Urine concentration of nuclear matrix
protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J
2008, 5:243-247.
8. von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G:
Characterization of the translocation breakpoint sequences of two DEK-
CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-
CAN fusion gene found in a case of acute undifferentiated leukemia.
Genes Chromosomes Cancer 1992, 5:227-234.
9. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA: Amplification and
overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer
2005, 4:16.
10. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H:
DEK Expression is controlled by E2F and deregulated in diverse tumor
types. Cell Cycle 2006, 5:1202-1207.
11. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS,
Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR: The identification
of novel therapeutic targets for the treatment of malignant brain
tumors. Cancer Lett 2000, 156:191-198.
12. Szer IS, Sierakowska H, Szer W: A novel autoantibody to the putative
oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J
Rheumatol 1994, 21:2136-2142.
13. Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH:
Autoantibodies to DEK oncoprotein in a patient with systemic lupus
erythematosus and sarcoidosis. Arthritis Rheum 1998, 41:1505-1510.
14. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI:
Apoptosis inhibition by the human DEK oncoprotein involves
interference with p53 functions. Mol Cell Biol 2006, 26:7506-7519.
15. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K,
Wells SI: The human DEK proto-oncogene is a senescence inhibitor and
an upregulated target of high-risk human papillomavirus E7. J Virol 2005,
79:14309-14317.
16. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-
Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI: Overexpression of
the cellular DEK protein promotes epithelial transformation in vitro and
in vivo. Cancer Res 2009, 69:1792-1799.
17. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ,
Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C: Gene discovery in
bladder cancer progression using cDNA microarrays. Am J Pathol 2003,
163:505-516.
18. Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M,
Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D, et al: The DEK nuclear
autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006,
26:9484-9496.
19. Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J,
Fradet Y, Lim G, Marrano P, Zielenska M, Squire JA: Defining a 0.5-mb
region of genomic gain on chromosome 6p22 in bladder cancer by
quantitative-multiplex polymerase chain reaction. Am J Pathol 2004,
164:285-293.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/234/prepub
doi:10.1186/1471-2407-11-234
Cite this article as: Datta et al.: Oncoprotein DEK as a tissue and urinary
biomarker for bladder cancer. BMC Cancer 2011 11:234.
Datta et al. BMC Cancer 2011, 11:234
http://www.biomedcentral.com/1471-2407/11/234
Page 7 of 7